1.Nichols, RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44:19–23.
2.Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry: Uncomplicated and Complicated Skin and Skin Structure Infections—Developing Antimicrobial Drugs for Treatment. Washington, DC: Food and Drug Administration, US Department of Health and Human Services; 1998.
3.Graham, DR, Lucasti, C, Malafaia, O, et al.Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002;34: 1460–1468.
4.Graham, DR, Talan, DA, Nichols, RL, et al.Once-daily, high-dose levo-floxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002;35:381–389.
5.Li, JZ, Willke, RJ, Rittenhouse, BE, Rybak, MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 2003;4:57–70.
6.Deery, HG II. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clin North Am 1998;12:935–949.
7.Nichols, RL, Florman, S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33:S84–S93.
8.Fung, HB, Chang, JY, Kuczynski, S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63:1459–1480.
9.Doern, GV, Jones, RN, Pfeiler, MA, Kugler, KC, Beach, ML, SENTRY Study Group (North America). Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999;34:65–72.
10.Summanen, PH, Talan, DA, Strong, C, et al.Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 1995;20:S279–S282.
11.Nathwani, D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother 2003;51:ii37–ii44.
12.Boyce, JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol 1992;13:725–737.
13.Stevens, DL, Bisno, AL, Chambers, HF, et al.Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–1830.
14.Cattan, P, Yin, DD, Sarfati, E, Lyu, R, De Zelicourt, M, Fagnani, F. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002;21:787–793.
15.Deyo, RA, Cherkin, DC, Ciol, MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
16.Wilson, SE, Solomkin, JS, Le, V, Cammarata, SK, Bruss, JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003;185:369–375.
17.Duan, N. Smearing estimate: a nonparametric retransformation model. J Am Stat Assoc 1983;78:605–610.
18.Efron, B, Tibshirani, R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986;1:54–77.
19.Raghavan, M, Linden, PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621–1642.
20.Moet, GJ, Jones, RN, Biedenbach, DJ, Stilwell, MG, Fritsche, TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57:7–13.
21.Stevens, DL, Bisno, AL, Chambers, HF, et al.Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–1406.
22.Naimi, TS, LeDell, KH, Como-Sabetti, K, et al.Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976–2984.
23.US Department of Health and Human Services, Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) net. Available at: http://hcupnet.ahrq.gov/. Accessed February 22, 2007.
24.Rennie, RP, Jones, RN, Mutnick, AH, the SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45:287–293.
25.Lee, SY, Kuti, JL, Nicolau, DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6:283–295.
26.van der Eerden, MM, Vlaspolder, F, de Graaff, CS, et al.Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomized study. Thorax 2005;60:672–678.
27.Krobot, K, Yin, D, Zhang, Q, et al.Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682–687.
28.Falagas, ME, Barefoot, L, Griffith, J, Ruthazar, R, Snydman, DR. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913–921.
29.Dupont, H, Mentec, H, Sollet, JP, Bleichner, G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001;27:355–362.
30.Ruiz, M, Torres, A, Ewig, S, et al.Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000;162:119–125.
31.Kollef, MH, Sherman, G, Ward, S, Fraser, VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.
32.Kollef, MH, Ward, S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412–420.
33.Sanchez-Nieto, JM, Torres, A, Garcia-Cordoba, F, et al.Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998;157:371–376.
34.Rello, J, Rue, M, Jubert, P, et al.Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997;25:1862–1867.
35.Luna, CM, Vujacich, P, Niederman, MS, et al.Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676–685.
36.Alvarez-Lerma, F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22:387–394.
37.Mosdell, DM, Morris, DM, Voltura, A, et al.Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543–549.